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Abstract 35 
Bloodstream infections by Salmonella enterica serovar Typhimurium (S. 36 
Typhimurium) constitute a major health burden in sub-Saharan Africa (SSA). These 37 
invasive non-typhoidal (iNTS) infections are dominated by isolates of the antibiotic 38 
resistance-associated sequence type (ST) 313. Here, we report the emergence of a 39 
novel ST313 sublineage we name II.1 in the Democratic Republic of the Congo 40 
(DRC). Sublineage II.1 exhibits extensive drug resistance (XDR), involving a 41 
combination of multidrug resistance (MDR), extended spectrum betalactamase 42 
(ESBL) production and azithromycin (AZI) resistance. ST313 lineage II.I isolates 43 
harbour an IncHI2 plasmid we name pCST313 and some isolates also exhibit 44 
decreased ciprofloxacin susceptibility (DCS). Whole genome sequence analysis 45 
revealed ST313 II.I isolates have accumulated genetic signatures potentially 46 
associated with altered pathogenicity and host adaptation, in relation to changes 47 
observed in biofilm formation and metabolic capacity. Sublineage II.1 emerged at the 48 
beginning of the 21st century and is involved in on-going outbreaks. Our data 49 
provides evidence of further evolution within the ST313 clade of S. Typhimurium 50 
associated with iNTS in SSA. 51 
  52 
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Introduction 53 
Salmonella enterica subspecies enterica serovar Typhimurium (S. Typhimurium) and 54 
other non-typhoidal Salmonella are common causes of gastrointestinal infections in 55 
people living in industrialized countries 
1
. However, in sub-Saharan Africa (SSA), 56 
invasive non-typhoidal Salmonella (iNTS) bloodstream infections 
2
 are common 57 
totaling ~3.4 million cases annually, with S. Typhimurium being responsible for 58 
approximately two-thirds of these cases. The fatality rate in iNTS can be extremely 59 
high 
3,4
. 60 
In SSA, iNTS patients often do not suffer from diarrhea but instead display symptoms 61 
of fever and septicemia 
5
. There has been no proven zoonotic source of ST313 62 
infections and human to human transmission has been postulated 
6-8
. The disease 63 
disproportionately affects children under five years old and HIV positive adults 
9
.  64 
Whereas the majority of S. Typhimurium associated with gastroenteritis in developed 65 
countries belong to sequence types (ST) 19 and 34, S. Typhimurium iNTS in SSA are 66 
predominantly of ST313 
10
. The population structure of S. Typhimurium ST313 is 67 
dominated by two clonal lineages, named I and II, that sequentially spread over SSA 68 
in the past 40 years 
11
. The success of these ongoing pandemics has been attributed to 69 
resistance to antibiotics and the emergence of  HIV 
11,12
. The majority of iNTS S. 70 
Typhimurium isolated in the past 10 years have been of ST313 lineage II 
13-15
.  71 
S. Typhimurium ST313 isolates are predominantly multidrug resistant (MDR), 72 
implying co-resistance to the three former first line antibiotics ampicillin, 73 
trimethoprim/sulfamethoxazole and chloramphenicol 
16,17
. Two recent genomics-74 
based studies reported the acquisition of extended-spectrum β-lactamases (ESBLs), 75 
conferring resistance to the third generation cephalosporin ceftriaxone, among S. 76 
Typhimurium ST313 lineage II isolates from Malawi and Kenya 
13,14
. Ceftriaxone is a 77 
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recommended antibiotic to treat complicated iNTS, while the fluoroquinolone 78 
ciprofloxacin is recommended for uncomplicated iNTS 
18
. 79 
The genomes of S. Typhimurium ST313 show evidence of specialization towards a 80 
narrow host range by pseudogenization in a pattern that resembles that found in the 81 
host restricted typhoidal Salmonella S. Typhi 
5,19,20
. The genotypic differences 82 
between ST313 and ST19 isolates have been confirmed as phenotypes associated with 83 
host virulence and other traits, such as biofilm formation which has been postulated to 84 
influence both survival in the environment and macrophages 
11,21-25
. 85 
Here, we report the emergence of a novel extensively drug resistant (XDR) ST313 86 
sublineage, we name II.1, which is currently causing bloodstream infections in the 87 
Democratic Republic of the Congo (DRC) and represents > 10 % of all S. 88 
Typhimurium isolated in the Kongo Central Province 
17
. This sublineage is associated 89 
with a combination of MDR, ESBL production and resistance to azithromycin (AZI). 90 
Additionally, whole genome sequencing of multiple genomes identified signatures 91 
associated with pathogenicity, metabolism and potentially host adaptation.  92 
 93 
Results 94 
1. An XDR S. Typhimurium ST313 sublineage II.1 is emerging in the DRC 95 
Invasive S. Typhimurium have been isolated in different hospital sites across DRC 96 
during ongoing microbial surveillance of bacterial bloodstream infections 
17,26,27
. As 97 
third generation cephalosporins and AZI have been used in treatment we have 98 
monitored susceptibility using both phenotypic and genetic approaches. 99 
Consequently, to investigate the emerging phenotype of ESBL production and AZI 100 
resistance, a selection of 81 S. Typhimurium isolates from the region were subjected 101 
to whole genome sequence analysis. Their year and place of origin, the age of the 102 
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patient and their phenotypic antimicrobial susceptibility are listed in Supplemental 103 
Table 1. Of this panel, 54 S. Typhimurium isolates exhibited AZI resistance and were 104 
ESBL positive; all except three were also MDR and are thus classifiable as XDR. The 105 
isolates were collected from 2008 to 2016 in western (Kisantu, Kongo Central 106 
Province n=50; Kinshasa n=2) and northeastern DRC (Kisangani, Tshopo Province: 107 
n=2) (Fig. 1). Minimum inhibitory concentration (MIC) values for AZI resistance 108 
were between 32 and >256 mg/l. Two of these isolates, 5390_4 (Kisangani, 2016) and 109 
2735 (Kinshasa, 2008), showed decreased susceptibility to the fluoroquinolone 110 
ciprofloxacin (decreased ciprofloxacine susceptibility (DCS), MIC values of 0.38 and 111 
0.19 mg/l against ciprofloxacin respectively). These isolates also exhibited resistance 112 
to the quinolone pefloxacin, and susceptibility (5390_4) or resistance (2735) to the 113 
quinolone nalidixic acid. The other 27 S. Typhimurium isolates form a representative 114 
local context, originating from bloodstream infections in the same surveillance sites in 115 
DRC (see Supplementary Note). They were isolated between 2007 and 2016, and 116 
show no ESBL production nor resistance to AZI. The majority of these isolates (22 117 
out of 27) were MDR. One isolate, 16755_3 (Kisantu, 2016), exhibited DCS with a 118 
MIC value of 0.19 mg/l. 119 
Multilocus sequence typing (MLST) confirmed that all belong to ST313. An optimal 120 
context for the genomic analysis was obtained by including 153 African 
11,14,15,28,29
 121 
and 42 non-African 
11
  S. Typhimurium genomes in the overall analysis. The complete 122 
list of 276 analyzed S. Typhimurium genomes with the year, place and source of 123 
isolation is presented in Supplemental Table 2. 124 
This analysis revealed a novel sublineage II.1 in DRC defined by the most recent 125 
common ancestor of the monophyletic sublineage of 51 XDR isolates (Fig. 2.A). One 126 
isolate, 5390_4, originating from Kisangani (2016) while being MDR, ESBL 127 
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producing, AZI resistant and showing DCS, falls outside sublineage II.1, but is part of 128 
the clonal lineage II. All 27 control isolates also fell into lineage II, with two older 129 
isolates from Kisantu (2009) being most closely related to sublineage II.1 (1577 and 130 
1582).  131 
The S. Typhimurium ST313 lineage I and II in our study accumulated respectively 132 
225 and 216 conserved single nucleotide polymorphisms (SNPs) in their core 133 
genomes compared to their most recent common ancestor (Supplemental Fig. 1), 134 
which is comparable to previous observations 
20
. In comparison to the lineage II 135 
clade, sublineage II.1 isolates, except 2735, accumulated an additional 38 conserved 136 
core SNPs, and show a clonal structure with little substructure (Fig. 2b). Of note, the 137 
two isolates showing an AZI MIC value > 256 mg/l form a monophyletic clade within 138 
sublineage II.1 (17399_3 and 17568_3). No SNPs were acquired in known genes 139 
involved in macrolide resistance 
30
, but both isolates have a G118V amino acid 140 
substitution in the ABC-transporter protein BtuC. This SNP, in addition to the 141 
presence of mphA, might be involved in the observed increased AZI resistance 
31
. 142 
Cephalosporin resistant ST313 lineage II infections were previously reported from 143 
Kenya and Malawi 
13-15
. The XDR isolates we describe here form a novel ST313 144 
sublineage II.1. 145 
The putitive origin of the ST313 lineage II was previously predicted to be the DRC 
11
. 146 
Consequently, we applied a temporal reconstruction using BEAST2 to the S. 147 
Typhimurium ST313 lineage II and II.1 isolates. This limited analysis indicates that 148 
sublineage II.1 may have emerged in the DRC around 2004 (95% highest probability 149 
density (HPD) interval: 2000-2007) (Fig. 3).  150 
 151 
2. Lineage II.1 harbours a novel IncHI2 resistance plasmid, pCST313 152 
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A comprehensive resistome, composed of all catalogued genetic determinants for 153 
AMR, was bioinformatically extracted from the sequencing data (Supplemental Table 154 
2). This analysis indicated that the MDR phenotype observed in S. Typhimurium  155 
ST313 lineage II and sublineage II.1 isolates is associated with genes predicted to 156 
confer resistance to chloramphenicol (catA), ampicillin (blaTEM1) and trimethoprim 157 
(dfrA). While lineage II is linked to the presence of dfrA1, this allele is replaced by 158 
dfrA14 in sublineage II.1. XDR sublineage II.1 isolates harbour blaSHV-2A and mphA 159 
genes, respectively potentially associsated with resistance to cephalosporins and 160 
azithromycin. Identical blaSHV-2A and mphA genes are present in the ESBL positive, 161 
AZI resistant lineage II isolate from Kisangani (5390_4). One sublineage II.1 isolate, 162 
2735, shows DCS (MIC value ciprofloxacin = 0.19 g/l) in addition to AZI resistance 163 
and ESBL production and harbours a mutation in gyrA (D87N) associated with DCS. 164 
DCS combined with ESBL positivity and AZI resistance was also observed in the 165 
lineage II isolate 5390_4 (Kisangani, 2016, MIC value ciprofloxacin = 0.38 g/l), 166 
which has acquired a qnrS gene. The lineage II isolate 16755_3 (Kisantu, 2016, MIC 167 
value ciprofloxacin = 0.19 g/l), showing DCS but no ESBL activity nor AZI 168 
resistance and harbours a S83Y mutation in gyrA. 169 
All sublineage II.1 isolates as well as the lineage II 5390_4 isolate (ESBL + AZI) 170 
from Kisangani harbour a IncHI2 plasmid. IncHI2 plasmids have been reported 171 
previously in other S. Typhimurium ST313 isolates from Kenya (pKST313) and 172 
Malawi (pSTm-A54650) 
13,14
. We have named the novel “Congolese” IncHI2 plasmid 173 
pCST313, in analogy to the Kenyan pKST313 IncHI2 plasmid 
13
. The full pCST313 174 
plasmid sequence associated with sublineage II.1 was determined using PacBio 175 
sequencing of isolate 10433_3 (Kisantu, 2014). pCST313 is 274,695 nucleotides (Fig. 176 
4) and is highly conserved among all sublineage II.1 isolates, differing by ~5 single 177 
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SNPs between isolates. The known AMR determinants of ST313 sublineage II.1 are 178 
located on pCST313, as well as genes associated with heavy metal resistance against 179 
silver and copper. pCST313 encodes a potentially active TraB conjugation protein 180 
and conjugation operon 
32
. 181 
pCST313 exhibits significant similarity to R478 (99% identity over 86% coverage of 182 
pCST313), a self-transferable IncHI2 plasmid isolated from Serratia marcescens in 183 
1969 in the USA 
33
. Pairwise sequence comparisons of pCST313 with the other 184 
IncHI2 plasmids (1) pKST313 from Kenya, (2) pSTm-A54650 from Malawi, a (3) 185 
draft assembly from the IncHI2 plasmid of 5390_4 from Kisangani and R478 186 
revealed significant similarity between the plasmid backbones (Fig. 4 and 187 
Supplemental Table 3). The less conserved regions of pCST313 include antimicrobial 188 
resistance genes, flanked by transposon-associated regions (Fig. 4). 189 
 190 
3. The gemomes of S. Typhimurium ST313 lineage II.1 exhibit genetic 191 
signatures of altered pathogenicity and host adaptation 192 
ST313 sublineage II.1 harbours multiple chromosomal sequence differences in 193 
comparison to ST313 lineage II isolates (Figure 5). A deletion of 1076 nt was 194 
observed in the chromosome of ST313 sublineage II.1, resulting in loss of fljB. The 195 
fljB gene codes for the phase 2 flagellin protein which polymerizes to form the 196 
bacterial flagella (Supplemental Fig. 4). Loss of fljB (FljB) was confirmed at the DNA 197 
and protein level (Supplemental Fig. 5). Consequently, in contrast to their biphasic 198 
ancestors, sublineage II.1 isolates are monophasic as they only harbour the phase 1 199 
flagellin gene, fliC.  200 
We annotated the SNPs that are acquired in ST313 sublineage II.1 relative to lineage 201 
II (Supplemental Table 4). Of these SNPs, 19 are present in coding regions and cause 202 
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predicted non-synomynous mutations in the protein sequence (Supplemental Table 4). 203 
Seven of these 19 SNPs are located in conserved Pfam protein domains resulting in 204 
deviant bitscores. Consequently, we prioritized these SNPs as the most likely to cause 205 
functional defects. The affected genes are geranyltranstransferase ispA, methyl-206 
accepting chemotaxis protein trg_1, precorrin-3B C17-methyltransferase cbiH, 207 
propanediol dehydratase reactivation protein, outer membrane assembly protein 208 
asmA, putative multidrug export ATP-binding/permease protein SAV1866 and 209 
putative diguanylate cyclase yhjK. These genes have been linked to host-adaptation 210 
(cbiH) 
19
, virulence associated processes (asmA) 
34
 and chemotaxis during infection 211 
(trg_1) 
35
. Of note, these molecular processes are also linked to pseudogene 212 
acumulation in the phylogeny from S. Typhimurium ST19 to ST313 lineage II 
20
. 213 
As our interpretations are likely biased by the available literature, we applied a data 214 
mining approach to obtain a more objective evaluation of the association between the 215 
acquired SNPs in sublineage II.1 and invasiveness. Hereto, the Salmonella 216 
invasiveness index of each strain was calculated, which is based on the genomic 217 
signatures for S. enterica associated with adaptation to an invasive lifestyle 
36
. We 218 
observe an increase in invasiveness index from non-ST313 and ST313 lineage I 219 
strains to lineage II, and a significant further increase of the invasiveness index from 220 
lineage II to lineage II.1 (Fig. 6a, Supplemental Fig. 5). 221 
In addition to the observed genomic differences, S. Typhimurium ST313 sublineage 222 
II.1 isolates exhibited measurably different phenotypes compared to S. Typhimurium 223 
ST313 lineage II. A red dry and rough (RDAR) biofilm assay was performed that uses 224 
agar plates with stains that reveal extracellular matrix production in colonies. In this 225 
assay, S. Typhimurium ST313 lineage II isolates lost the rough morphotype compared 226 
to ST19, changing from a red, dry and rough (rdar) to a brown and smooth (bas) 227 
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phenotype. This phenotype was shown previously to be due to defective production of 228 
cellulose, one of the two major extracellular components of Salmonella biofilms 
21,23
. 229 
Interestingly, S. Typhimurium ST313 lineage II.1 shows a further defect in biofilm 230 
formation. Sublineage II.1 isolates have a smooth and white (saw) colony morphotype 231 
in this assay, whereas sublineage II isolates have a brown and smooth (bas) 232 
morphotype (Fig. 6b). This phenotypic defect is consistent across all isolates from 233 
sublineage II.1 and resembles the S. Typhi morphotype. The exception was isolate 234 
2735 (Kinshasa, 2008), the phylogenetically oldest representative of sublineage II.1 235 
(Supplemental Fig. 6) 
22
. Among the SNPs that were acquired in sublineage II.1 236 
compared to lineage II, none were located in or near genes responsible for the 237 
production of curli, which is another major biofilm compound. Mutagenesis 238 
experiments showed that the introduction of a null mutation into the asmA gene of S. 239 
Typhimurium ST313 lineage II D23580 partly recreated the sublineage II.1 biofilm 240 
phenotype (Fig. 6b), suggesting that the non-synomynous SNP in asmA might 241 
contribute to the biofilm defect. asmA encodes an outer membrane protein that was 242 
previously described to be involved in the invasion of epithelial cells 
34
. Targeted 243 
mutations in wzxC, yhjJ and yhjK in D23580 had no obvious effect on the biofilm 244 
phenotype (Supplemental Fig. 7). 245 
While Salmonella causing gastrointestinal infections typically have a relatively large 246 
metabolic capacity, strains causing invasive infections generally have a more limited 247 
capacity 
37
. We used Biolog Phenotype Microarrays to assess growth on 192 different 248 
metabolic compounds between two representative isolates of both lineage II and 249 
lineage II.1. Lineage II.1 isolates showed significant lower metabolic capacity for 250 
carbon compounds compared to lineage II isolates (Supplemental Table 5). The effect 251 
was most pronounced for D-galactonic acid γ-lacton (Supplemental Fig. 8). 252 
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We also assessed the phenotypic behaviour of five representative sublineage II.1 253 
isolates in in vitro and in vivo models. Human macrophage cell killing assays, 254 
intravenous and oral mice infections did not show significant differences between the 255 
lineages, although two sublineage II.1 isolates showed an overall lower infection of 256 
THP macrophages and cell counts in mice deep tissue after intravenous infections 257 
(Supplemental Fig. 9, 10 and 11). 258 
 259 
Discussion 260 
Here, we report the emergence of a novel S. Typhimurium ST313 sublineage II.1 261 
from the DRC with unprecedented levels of AMR. The World Health Organisation 262 
(WHO) has listed Salmonella spp. as one of the pathogens for which new antibiotics 263 
are urgently needed 
38
. In addition to the MDR phenotype of lineage II 
11
, sublineage 264 
II.1 is associated with ESBL activity, AZI resistance and occasional DCS, thereby 265 
giving rise to the first lineage of XDR iNTS. As there is no XDR definition for iNTS 266 
yet, we extrapolate the definition from XDR Salmonella enterica subspecies enterica 267 
serovar Typhi (S. Typhi), recently defined as resistance to five antibiotics (observed 268 
as MDR combined with resistance against fluoroquinolones and ESBL activity), 269 
thereby using the same nomenclature as for other bacterial pathogens 
39,40
. The XDR 270 
iNTS isolates from this study show MDR in combination with resistance to the two 271 
alternative treatment options ceftriaxone and AZI. 272 
Sublineage II.1 was identified in three independent surveillance sites in the DRC, 273 
suggesting this sublineage is relatively widespread in the region, although further 274 
surveillance is required to confirm the burden 
17,41-43
. 275 
All except three of the S. Typhimurium ST313 lineage II.I isolates described here fall 276 
into the XDR category defined for S. Typhi 
39,40
. Within the  DRC setting, the only 277 
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available antibiotic for treatment of XDR iNTS infections are fluoroquinolones. 278 
Importantly, DCS iNTS is present in DRC, with one pan-resistant (XDR + DCS) 279 
isolate identified in this study. The use of fluoroquinolones might cause serious side 280 
effects involving muscles, tendons, bones and the nervous system recently urging the 281 
European Medicines Agency Pharmacovigilance Risk Assessment Committee 282 
(PRAC) to recommend restricting the use 
44
. As a consequence, the emergence of this 283 
XDR iNTS sublineage II.1 increases the urgency for advancements in other strategies 284 
to combat the disease, such as vaccination. 285 
Antibiotic use might have provided the selection pressure driving the emergence of 286 
this sublineage. Within SSA, the antibiotic AZI has been used in mass drug 287 
administrations for the elimination of Trachoma, and has also recently been tested to 288 
reduce childhood mortality 
45,46
. In the DRC, it is not clear which antibiotics are in 289 
routine use, as only 30% of patients have access to the regular healthcare system, and 290 
40% rely on self-medication 
47
. MDR in ST313 sublineage II.1 is linked here with the 291 
IncHI2 plasmid pCST313. Intriguingly, previous reports have associated iNTS S. 292 
Typhimurium in SSA with IncHI2 plasmids 
13,14,48
.  293 
The acquisition of antibiotic resistance and the accumulation of genomic signatures 294 
associated with host adaptation by sublineage II.1 suggest further specialization to a 295 
human niche 
49,5012,20,21
. Sublineage II.1 are monophasic, a phenotype similar to 296 
typhoidal Salmonella 
50
. A large recombination event took place at the fljB locus, 297 
resulting in loss of phase II flagellin production, while the phase I flagellin gene fliC 298 
remained intact. Bacterial flagellin plays an important role in the host innate immune 299 
response and is a stimulator of innate immunity through Tlr5 
51,52
.  Strikingly, a 300 
pandemic of monophasic S. Typhimurium ST34 causing gastro-intestinal infections 301 
has recently been identified, with some strains of this pandemic causing bloodstream 302 
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infections in Vietnam 
53,54
. Sublineage II.1 have a reduced capacity to form 303 
multicellular communities compared to lineage II 
21
, again with similarity to S. Typhi 304 
22
. Bacterial biofilms are important for both resistance to environmental stresses and 305 
survival outside the host. S. Typhimurium ST313 sublineage II.1 isolates also show a 306 
lower capacity for the metabolism of carbon sources, in line with the findings that S. 307 
Typhimurium ST313 has a reduced metabolic capacity compared to S. Typhimurium 308 
ST19 
20
. 309 
Survival in macrophages was experimentally assessed, given the observed mutations 310 
in sublineage II.1, such as loss of fljB, which can affect macrophage survival 
23
. 311 
However, we did not find significant differences between lineage II and sublineage 312 
II.1 in macrophage infection assays. Likewise, II.1 isolates did not show a 313 
reproducible increased colonization of deeper tissue during intravenous or oral mouse 314 
infections. Although our genomic, biofilm and metabolic data show signatures for 315 
increased human adaption of lineage II, S. Typhimurium ST313 lineage II.I isolates 316 
are thus not host restricted.  317 
In conclusion, in this study we identified an on-going outbreak of a novel sublineage 318 
II.1 emerging from the current African S. Typhimurium ST313 pandemic. Sublineage 319 
II.1 is associated with XDR driven by an IncHI2 plasmid named pCST313, 320 
harbouring resistance to AZI and ESBL production. In addition, sublineage II.1 also 321 
shows evolutionary signatures associated with host adaptation. Extended bloodstream 322 
surveillance in the endemic regions of S. Typhimurium ST313 will be crucial to 323 
further track the spread of XDR ST313 sublineage II.1 and to timely detect the 324 
emergence of new sublineages with novel antibiotic resistance profiles 325 
 326 
Methods 327 
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1. Selection of bacterial isolates from bloodstream surveillance  328 
The DRC isolates originated from blood cultures sampled at the referral hospital of 329 
Saint Luc in Kisantu (Kongo Central province), the University Hospital of Kinshasa, 330 
the referral Hospital St. Joseph and Monkole Hospital from Kinshasa (Kinshasa 331 
province), the referral hospital of Bwamanda (Tshopo province), the referral hospital 332 
of Kabondo and the university hospital of Kisangani (CUKIS) and associated health 333 
centers (Sud-Ubangi province) in the DRC 
17,27,43
. These hospitals have participated in 334 
the microbiological surveillance network since 2007 coordinated by the National 335 
Institute of Biomedical Research (INRB) in Kinshasa, DRC, in collaboration with the 336 
Institute of Tropical Medicine (ITM) in Antwerp, Belgium. Blood cultures were 337 
sampled in patients suspected of bloodstream infections according to standard 338 
indications and methods as described elsewhere 
17
. 339 
All available XDR S. Typhimurium available to this study were included (n=54). A 340 
sample of 27 representative non-XDR S. Typhimurium isolates were selected as 341 
controls for this analysis. Most health facilities across the country lack capacity for 342 
diagnosing bacterial bloodstream infections and we have therefore no information 343 
about bloodstream infections elsewhere in DRC except as part of outbreak research 344 
41,42
. The surveillance sites included in this study were not consistently active because 345 
of stock ruptures, staff movements, funding and insecurity. All isolates were stored in 346 
tubes of Trypticase Soya Agar (Oxoid, Basingstoke, UK) and shipped to ITM for 347 
confirmation and further identification. 348 
At ITM, isolates biochemically confirmed as Salmonella spp. were serotyped using 349 
commercial antisera (Sifin, Berlin, Germany) according to the Kauffmann-White 350 
scheme 
55
. A representative selection of the isolates (10%) was sent to the National 351 
Reference Centre in Belgium for confirmation of serotype. Antibiotic susceptibility 352 
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testing of all isolates was done by disk diffusion (Neo Sensitabs, Rosco, Taastrup, 353 
Denmark) according to the National Committee for Clinical Laboratory Standards 354 
(CLSI) guidelines; for ciprofloxacin and AZI, minimal inhibitory concentration 355 
(MIC-values) were determined with the E-test macromethod (bioMérieux). 356 
Interpretation of results was performed according to the most recent CLSI guideline 357 
56
. Isolates with intermediate susceptibility were considered resistant. MDR was 358 
defined as co-resistance to all three first-line antibiotics ampicillin, chloramphenicol 359 
and trimethoprim-sulfamethoxazole 
18
. Extended-spectrum β-lactamase (ESBL) 360 
production was assessed by double disk method according to CLSI guidelines 
56
. For 361 
ciprofloxacin, the susceptibility breakpoint of  ≤ 0.064 mg/L was used; the term 362 
“decreased ciprofloxacin susceptibility” was used to indicate MIC values > 0.064 363 
mg/L and < 1 mg/L, and “ciprofloxacin resistance” was reserved for MIC values ≥ 1 364 
mg/L 
56. For AZI, isolates were considered resistant at MIC values ≥ 16 mg/L 56. 365 
Ethical approval for the Microbiological Surveillance was granted by the Institutional 366 
Review Board at the ITM in Antwerp, by the Ethics Committees of the Antwerp 367 
University (Belgium) and the School of Public Health (Kinshasa, DRC). 368 
 369 
2. Illumina and Pacbio whole genome sequencing 370 
DNA from all 81 strains was purified using the Gentra PureGene Yeast/Bact Kit 371 
(Qiagen, Hilden, Germany), following the manufacturer‟s guidelines and DNA was 372 
sequenced on an Illumina HiSeq platform (Illumina, San Diego, USA). Illumina 373 
adapter content was removed from the reads using Trimmomatic v.0.33 
57
.  Public 374 
available Illumina sequencing data from 153 Salmonella Typhimurium strains 375 
originating from DRC, Mali, Nigeria, Uganda, Kenya, Malawi and Mozambique and 376 
a selection of 42 non-African genomes were included in the further genomics analysis 377 
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11,13-15,29
. This is a convenience sample including all publicly available African iNTS 378 
genomes. Strains are summarized in Supplemental Table 2. 379 
A high-quality reference genome sequence of sublineage II.1 isolate 10433_3 was 380 
constructed using the PacBio RS II platform (PacBio, Menlo Park, CA, USA). The 381 
PacBio Template Prep Kit (PacBio, Menlo Park, CA, USA) and BluePippin™ Size 382 
Selection System protocol were used to prepare size-selected libraries (20kb) from 5 383 
μg of sheared and concentrated DNA. Sequencing was performed using the magnetic 384 
bead collection protocol, a 20,000 bp insert size, stage start, and 180-minute movies. 385 
Sequence reads were assembled using HGAP v3 28 of the SMRT analysis software 386 
v2.3.0 (Pacbio, Menlo Park, CA, USA). The fold coverage to target when picking the 387 
minimum fragment length for assembly was set to 30 and the approximate genome 388 
size was set to 3Mbp. The assembly was circularized using Circlator v1.1.3 
58
. 389 
Finally, the circularized assembly was polished using the PacBio RS_Resequencing 390 
protocol and Quiver v1 of the SMRT analysis software v2.3.0 
59
. Automated 391 
annotation was performed using PROKKA v1.11 
60
 and genus specific databases from 392 
RefSeq 
61
. The final assembled bacterial chromosome consisted of 4,877,289 bp, and 393 
two plasmid sequences of 274,695 bp and 94,649 bp.  394 
 395 
3. Read mapping, variant detection and phylogenetic analysis 396 
Illumina HiSeq reads were mapped to the Salmonella Typhimurium reference 397 
genomes of ST313 lineage II (D23580, FN424405.1, 
12
) and ST313 sublineage II.1 398 
(10433_3, this study) using SMALT v0.7.4 to produce a BAM file. 399 
SMALT was used to index the reference using a kmer size of 20 and a step size of 13 400 
and the reads were aligned using default parameters but with the maximum insert size 401 
set as 3 times the mean fragment size of the sequencing library. PCR duplicate reads 402 
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were identified using Picard v1.92 (Broad Institute, Cambridge, MA, USA) and 403 
flagged as duplicates in the BAM file.  404 
Variation detection was performed using samtools mpileup v0.1.19 with parameters 405 
“-d 1000 -DSugBf” and bcftools v0.1.19 62 to produce a BCF file of all variant sites. 406 
The option to call genotypes at variant sites was passed to the bcftools call. All bases 407 
were filtered to remove those with uncertainty in the base call. The bcftools variant 408 
quality score was required to be greater than 50 (quality < 50) and mapping quality 409 
greater than 30 (map_quality < 30). If not all reads gave the same base call, the allele 410 
frequency, as calculated by bcftools, was required to be either 0 for bases called the 411 
same as the reference, or 1 for bases called as a SNP (af1 < 0.95). The majority base 412 
call was required to be present in at least 75% of reads mapping at the base, (ratio < 413 
0.75), and the minimum mapping depth required was 4 reads, at least two of which 414 
had to map to each strand (depth < 4, depth_strand < 2). Finally, strand_bias was 415 
required to be less than 0.001, map_bias less than 0.001 and tail_bias less than 0.001. 416 
If any of these filters were not met, the base was called as uncertain.  417 
A pseudo-genome was constructed by substituting the base call at each site (variant 418 
and non-variant) in the BCF file into the reference genome and any site called as 419 
uncertain was substituted with an N. Insertions with respect to the reference genome 420 
were ignored and deletions with respect to the reference genome were filled with N‟s 421 
in the pseudo-genome to keep it aligned and the same length as the reference genome 422 
used for read mapping. 423 
Recombinant regions in the chromosome such as prophage regions and the fljB ORF 424 
in the chromosome were removed from the alignment and checked using Gubbins 425 
v1.4.10 
63
. SNP sites were extracted from the alignment using snp-sites 
64
 and used to 426 
construct a maximum likelihood phylogeny. RAxML v8.2.8 
65
 with substitution 427 
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model GTRCAT. Support for nodes on the trees was assessed using 1000 bootstrap 428 
replicates. A comprehensive tree, with reads mapped to ST313 lineage II (D23580, 429 
FN424405.1, 
12
)  was rooted on S. Paratyphi A270 (ERR326600). Based on this tree, 430 
lineage II and sublineage II.1 isolates were identified and a high-resolution lineage II 431 
tree was constructed based on mapping to ST313 sublineage II.1 (10433_3, this 432 
study) and rooted to S. Typhimurium ST313 strain DT2. Trees were visualized using 433 
Figtree v1.4.2 and iTOL 
66
. The comprehensive phylogenetic tree with spatiotemporal 434 
metadata, based on mapping against D23580 and rooted on S. Paratyphi A270 is made 435 
publicly available on MicroReact 
67
 (https://microreact.org/project/9f_SsS82d, 436 
Supplemental Fig. 2). 437 
 438 
4. Bayesian phylogenetic & phylogeographic analysis 439 
We used BEAST2 v2.4.8 
68
 to date evolutionary events, determine the substitution 440 
rate and produce a time-tree of African S. Typhimurium with tip-dates defined as the 441 
year of isolation (Supplemental Table 2). BEAUti xml‟s were manually modified to 442 
specify the number of invariant sites in the genome. We employed a general time 443 
reversible (GTR) substitution model with gamma distributed rate heterogeneity. In 444 
addition, an uncorrelated log-normal relaxed molecular clock 
69
 was used to model the 445 
variation of evolutionary (substitution) rates across branches. The extended Bayesian 446 
skyline plot (EBSP) demographic method 
70
 was selected as this model does not 447 
depend on a prespecified parametric model of demographic history and the method 448 
has been proven to indicate the most appropriate demographic model for any given 449 
dataset. Earlier BEAST analyses on a related dataset identified the molecular clock 450 
model and tree prior used here to have the highest support by using Bayes factor (ratio 451 
of the marginal likelihoods of two competing models) based model selection 
11
. 452 
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All parameters were estimated jointly in a BEAST2 analysis using a total of 10 453 
independent chains of 500 million generations, with samples taken every 50,000 454 
MCMC generations. Log files were inspected in Tracer v1.6 for convergence, proper 455 
mixing, and to assess whether the chain length produced an effective sample size 456 
(ESS) for all parameters larger than 300, indicating sufficient sampling. LogCombiner 457 
v2.5.0 was used to combine log and tree files of the independent BEAST2 runs, after 458 
having removed a 30% burn-in from each run. Thus, parameter medians and 95% 459 
highest posterior density (HPD) intervals were estimated from 70,000 sampled 460 
MCMC generations. The entire analysis was replicated on five random subsets of 100 461 
taxa of the complete isolate panel to test if our results were affected by sampling bias.  462 
To ensure prior parameters were not over-constraining the calculations, the entire 463 
analysis was also run while sampling only from the prior, and the resulting parameter 464 
distributions were compared in Tracer. Finally, TreeAnnotator v2.5.2 was used to 465 
summarize the posterior sample of time-trees in order to produce a maximum clade 466 
credibility tree with the posterior estimates of node heights visualized on it.  467 
 468 
5. Genomic rearrangements and SNP analysis 469 
Large genomic rearrangements were identified by analysis of the aligned reference 470 
genome sequences using the Artemis Comparison Tool (ACT). 471 
A VCF file containing all SNP sites was extracted using snp-sites 
64
 from all strains 472 
included in this study. Conserved SNPs between lineage II and lineage II.1 strains 473 
were extracted using custom calculations in R v.3.3.3, thereby comparing SNPs with 474 
the D23580 reference sequence and annotation (FN424405.1). SNPs that were 475 
conserved in 51 of the 53 sublineage II.1 strains, and not present in lineage II strains 476 
were subjected to a functional analysis. These SNPs were functionally studied by 477 
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comparison with the D23580 annotation 
12
. Ortholog loci in S. Typhimurium LT2 478 
(NC_003197.2) were identified using BLASTN 2.6.0+. 479 
For SNPs present in coding regions, the effect of the SNP on the respective amino 480 
acid sequence was assessed. For non-synonymous SNPs, the PAM1 value and delta 481 
bitscore value was included. The higher the PAM1 value, the more frequent specific 482 
amino acid substitutions are observed. Delta bitscores were calculated by subtracting 483 
the bitscore for a given HMM domain in lineage II from the bitscore of the 484 
orthologous domain lineage II.1 strains 
71
. 485 
To calculate the invasiveness index per strain, sequence reads of each sample were 486 
mapped against the S. Typhimurium SL1344 reference genome (FQ312003.1) using 487 
BWA mem v0.7.12 
72
 to produce a BAM file. BWA was used to index the reference 488 
and the reads were aligned using default parameters but with the maximum insert size 489 
set as 3 times the mean fragment size of the sequencing library. 490 
Picard (http://broadinstitute.github.io/picard) was used to identify and flag optical 491 
duplicates generated during library preparation. SNPs and indels were called using 492 
samtools v1.2 mpileup 
73
, and were filtered to exclude those variants with coverage 493 
<10 or quality <30.  SNP calls were used to produce variant coding sequences. 494 
Protein sequences were then screened using phmmer to identify the closest homologs 495 
to the 196 predictive genes used by the invasiveness index model. These genes were 496 
then scored against profile hidden Markov models (HMMs) for these protein families 497 
from the eggNOG database to test for uncharacteristic patterns of sequence variation. 498 
Bitscores produced in the comparison of each protein sequence to its respective 499 
protein family HMM were then used as input to the model. The groups were 500 
compared using a Mann Whitney U test. 501 
 502 
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6. Sequence typing, resistance gene analysis and plasmid analysis 503 
Resistance genes were determined from the raw Illumina sequencing data using ariba 504 
v 2.11.1 
74
 with CARD database version 1.1.8 
75
. SNPs explaining a DCS phenotype 505 
was checked individually for strains showing DCS. The gyrA, gyrB, parC, parE, acrB 506 
sequences of reference sequence from S. Typhimurium LT2 (NC_003197.2) were 507 
compared to assemblies of the DCS strains using BLASTN 2.6.0+. The presence of 508 
plasmid replicons was determined from raw Illumina reads using SRST2 
76
 with the 509 
complementary P18 plasmid replicon database. 510 
The PacBio reference sequence of plasmid pCST313 (S. Typhimurium DRC, this 511 
study) was searched for similar nucleotide sequences publicly available using using 512 
NCBI Blast with the Nucleotide collection (nt), update 2017/07/13. Pairwise 513 
comparisons were done using BRIG 
77
. pCST313 was compared with plasmids R478 514 
(Serratia marcescens USA, BX664015), pKST313 (S. Typhimurium, LN794248) and 515 
pSTm-A54650 (S. Typhimurium, LK056646). A de novo assembly was performed 516 
based on Illumina sequences of isolate 5390_4 (This study) 
78
 and the assembly of the 517 
plasmid sequence was used for pairwise comparative analysis. Hereto, the contigs of 518 
the assembly were reordered using Mauve version 2015_02_25 
79
 and the 12 contigs 519 
homologous to pCST313 were retained for further analysis.  520 
 521 
7. Flagella expression 522 
Presence of fljB (FljB) and fliC (FliC) were confirmed at the DNA and protein level 523 
for a S. Typhimurium reference lineage II (isolate 9412_3) and sublineage II.1 524 
(10433_3) strain. DNA was extracted from both strains using Gentra Puregene 525 
Yeast/Bact. Kit (Qiagen, U.S.A) and PCR-amplified using fljB (forward GCT CCT 526 
GTC GCT TCA TCG TA, reverse ACG GTA CAG TAA CCC TTG CG) and fliC 527 
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(forward AAC AGA TGC TGT GCC GGT AA, reverse CTC GGC TAC TGG TCT 528 
TGG TG) specific primers. 529 
For protein samples, overnight cultures were centrifuged at 1500 g and pellets were 530 
suspended in 300µl phosphate-buffered saline (PBS, pH 7.4). The suspension was 531 
homogenized using FastPrep-24 (MP Biomedicals, Santa Ana, California, USA) and 532 
centrifuged at 15000 rpm. 10 µl of the supernatant was diluted 1:1 with sample buffer 533 
(Laemmle, Sigma-Aldrich, St. Louis, Missouri, US) before loading on SDS-page gel 534 
(12%). After running (45 min 100V) the gel was colored with Coomassie blue.  535 
 536 
8. Biofilm assays 537 
Strains were grown in 10 ml low salt LB Broth overnight, diluted 1:100 in phosphate-538 
buffered saline (PBS) and 5µl was spotted onto Red-Dry-Rough (RDAR) Phenotype 539 
plates (1.5% Agar, 1%  Tryptone, 0.5% Yeast Extract, 20 µg/ml Coomassie Brilliant 540 
Blue, 40 µg/ml Congo Red in water) 
80
. The plates were incubated at 27°C without 541 
inversion for 84 hours, phenotype analysed and photographed. Colonies were 542 
quantitatively analysed using the IRIS software 
81
. 543 
 544 
9. Biolog assays 545 
Four S. Typhimurium ST313 lineage II (12299_3, 9266_3, 9412_3 and D23580) and 546 
four S. Typhimurium sublineage ST313 sublineage II.1 (10393_3, 10433_3,12306_3 547 
and 8866_3) isolates were analysed on the OmniLog phenotype MicroArray (PM) 548 
platform, in three independent biological replicates each. Overnight cultures cells 549 
were transferred with a sterile swab to 15 ml IF-0 (12.5 ml IF-0 with 2.5 ml H2O) and 550 
stirred to obtain a uniform suspension. Turbidity of the suspension was adjusted to 551 
42% transmittance T by using the Biolog Turbidimeter. Plates PM 1 and PM 2 were 552 
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inoculated with 100µl per well of the cell suspension mix diluted 1:5 in IF-0 553 
containing 1.2% dye mix A. All plates were covered by anaerobic sealing foil (Roche) 554 
and incubated in the Omnilog phenotype MicroArray system for 48h at 37°C. 555 
Statistical calculations and visualization were done in R 
82
 by using the opm package 556 
83
. The curve parameters were estimated using spline fitting. The mean of the area 557 
under the curve (AUC) was compared between sublineage II.1 versus lineage II 558 
strains using a linear model based on a „Tukey‟-type contrast using the opm_mcp 559 
function from the multcomp package 
84
. 560 
 561 
10. Mutant construction 562 
Mutant strains S. Typhimurium D23580 ΔasmA, S. Typhimurium D23580 ΔyhjJ, S. 563 
Typhimurium D23580 ΔyhjK and S. Typhimurium D23580 ΔwxzC were constructed. 564 
Hereto, the Kanamycin resistance gene (kan) was PCR-amplified from pKD4 using 565 
Q5 HotStart DNA Polymerase (New England Biolabs, Massachusetts, U.S.A.) and 566 
gene specific oligos (Integrated DNA Technologies, Illinois, U.S.A.) for asmA 567 
(TGAGACGATTTCTGACGACGCTGATGATTCTCCTGGTCGTGCTGGTGGCCTGTGTAGGCTGGAGCTGCTTCG, 568 
GGCCTGCTGCACCAGTTGCTGGAAATTCATTCCTTCAAGGCGCGTATTGCCATATGAATATCCTCCTTAG), wxzc 569 
(GGCGCTAAATGGTCGGCTATCGCCACGATAGTGATTATCGGTCTGGGGTTTGTGTAGGCTGGAGCTGCTTCG, 570 
CCCCGCCAGATGGCCGCCAATGAGAATTGCCGGGATAAACAGAAACGTTTCATATGAATATCCTCCTTAG), yhjJ 571 
(GATCGTATTGAAGTTCGTCTCCAGGTTAATACCGGTTCGCTCACCGAAAGTATGTGTAGGCTGGAGCTGCTTCG, 572 
GATAGCTGCTGACGTAAATTCTGATTGAGCATATCAACGGTCAGGCTGTTGACATATGAATATCCTCCTTAG) and 573 
yhjK 574 
(CTGGTACAGCAGAACCGCTACAACACGGCTACGCAACTGGAAAGCATCGCTGTGTAGGCTGGAGCTGCTTCG, 575 
CAGGGTGCATGAGCTGTAACGCGGAAAGATTGACGGAGAGCGGCAATGTCCATATGAATATCCTCCTTAG). DNA 576 
was prepared by gel extraction (Qiagen, Hilden, Germany) and ethanol precipitation. 577 
  25 
The pSIM18 vector carrying the lambda RED recombinase system 
85
 was 579 
electroporated into S. Typhimurium D23580 using 10.5 ng DNA at  2.5 kV, 200 580 
ohms, 25 µF  (Bio-Rad MicroPulser, California, U.S.A.). The subsequent S. 581 
Typhimurium D23580::pSIM18 was used to create the mutant strains. 582 
S. Typhimurium D23580::pSIM18 was grown overnight and then diluted 1 in 100 the 583 
next day in low salt LB plus 100 µg/ml Hygromycin B (Thermo Fisher, 584 
Massachusetts, U.S.A.) and incubated for 3 hrs, shaking at 30 ᵒC to an OD590 of 0.4. 585 
The culture was spun for 10 min at 2500 x g and washed twice in ice cold 10% 586 
glycerol. The cell pellet was finally resuspended in 140 µl of 10% glycerol and 587 
electroporated with DNA (Table 1) in a precooled 2mm electroporation cuvette under 588 
conditions specified previously. Cells were then incubated in 500 µl of pre-warmed 589 
SOC outgrowth medium (New England Biolabs, Massachusetts, U.S.A.) at 37ᵒC for 2 590 
hr. 3 x 100 µl aliquots were plated onto 50 µg/ml Kanamycin (Thermo Fisher, 591 
Massachusetts, U.S.A.) LB plates and grown overnight at 37ᵒC. The remaining 592 
volume was left at room temperature overnight and plated on 50 µg/ml Kanamycin 593 
and left to grow at 37ᵒC. The knock-out mutation was confirmed using Illumina 594 
sequencing. 595 
 596 
11. THP-1 macrophage invasion and replication assay 597 
THP-1 monocytes (European Collection of Authenticated Cell Cultures, cat no. 598 
88081201) were plated at 1x10
5
 cells/well in RPMI (Gibco) with 2 mM L-glutamine 599 
(Sigma) and 10% fetal bovine serum (Sigma) with PMA (Phorbol 12-myristate 13-600 
acetate, (Sigma) to differentiate to macrophages. After 72 hours, media was changed 601 
to the supplemented RPMI (as defined above) for 24h before infection. Bacterial 602 
isolates SL1344, D23580, 2101, 9266/3, 12299/3, 6948/3, 9412/3, 10055/3, 8866/3, 603 
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12155/3, 10393/3, and 10433/3 were inoculated in 10 mL low-salt lysogeny broth 604 
(LB) from frozen stocks and incubated at 37°C, shaking for ~17.5 h prior to use. For 605 
infection, bacteria were diluted in PBS to an optical density (OD) of 1 before adding 606 
to RPMI. 500 µL of bacteria in media were added to cells for a multiplicity of 607 
infection of 20:1 and incubated at 37°C for 30 min. At 30 min, media containing 608 
bacteria was removed and replaced with media containing 0.1 mg/ mL gentamicin. 609 
For the 1 h invasion timepoint, at 1 h post-infection, cells were washed 1x in PBS 610 
then lysed in 1% Triton, and serial dilutions at 10
-1
, 10
-2
, 10
-3
 prepared in PBS. 50 µL 611 
of each dilution was spotted on LB agar plates in 10 µL spots and incubated at 37°C. 612 
For the 6 h intracellular replication timepoint, gentamicin-containing media was 613 
replaced by the supplemented RPMI at 1 h post-infection and incubated at 37°C for 614 
another 5 h. At 6 h post-infection, cells were washed 1 x in PBS and lysed with 1% 615 
Triton, as for the cells at the 1 h timepoint. Agar plates were incubated until colony 616 
forming units were visible for counting to calculate viable bacteria per mL. 617 
Experiments were done in three biological replicates and mean and standard error of 618 
the mean was calculated for all strains.  619 
 620 
12. Mouse infection 621 
 622 
Salmonella strains were grown static overnight in L broth at 37°C. Inoculations were 623 
prepared by diluting overnight culture in PBS. Inoculums were plated post infection 624 
on LB agar plates for confirmation. Groups of C57/Bl6 mice were infected 625 
intravenously with 2 x 10
2
 colony forming units (CFU) or orally with 2 x 10
6
 CFU 626 
with each Salmonella strain. At day 4 post infection mice were culled and organs 627 
removed. Homogenised organs were serially diluted in PBS and 20 µl of each dilution 628 
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were spotted into LB agar plates. CFUs were counted next day to calculate number of 629 
CFUs per organ. All experiments on animals were performed under a UK animal 630 
licence that has been through local ethical review before being approved by Sanger - 631 
Animal Welfare and Ethical Review Body (AWERB) and performed according to the 632 
regulations of the UK Home Office Scientific Procedures Act (1986). 633 
 634 
Data and material availability 635 
Sequence data that support the findings of this study have been deposited in SRA with 636 
accession codes as listed in Supplementary Table 1. The annotated Pacbio‟d reference 637 
genome of Salmonella Typhimurium strain 10433_3 is uploaded to Genbank with 638 
accession ID ERS1310131. The generated phylogenetic tree (as presented in Fig. 2a) 639 
is publicly accessible in MicroReact: https://microreact.org/project/ZfwCFTj2-640 
/d9f0ce6f. All other datasets generated during and/or analysed the current study are 641 
available from the corresponding author on reasonable request. Requests for obtaining 642 
biological material (mutant strains) should be addressed to the corresponding author. 643 
Exchange of clinical isolates should always be in agreement with the Institute of 644 
Tropical Medicine (Antwerp, Belgium) and Institut National Recherche Biomedicale 645 
(Kinshasa, DRC), co-owning the bacterial isolates. 646 
 647 
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Figure Legends 954 
 955 
Figure 1: Geographical origin of S. Typhimurium showing extended spectrum 956 
beta-lactamase (ESBL) production and azithromycin (AZI) resistance in the 957 
Democratic Republic of the Congo. 958 
Red dots with numbers (n) of the included resistant strains in the respective 959 
surveillance sites (Kinshasa, Kisangani and Kisantu).  960 
  35 
 961 
Figure 2: The population structure of S. Typhimurium ST313 in Africa and the 962 
emergence of a new sublineage ST313 II.1 963 
a. Maximum likelihood phylogenetic tree based on the 81 genome sequences 964 
from this study and 153 African and 42 non-African publicly available S. 965 
Typhimurium strains (summarized in Supplemental Table 2). Sequencing 966 
reads were mapped against S. Typhimurium ST313 lineage II reference strain 967 
D23580 
12
. The tree is based on 62884 chromosomal SNPs. Branches of S. 968 
Typhimurium ST313 sublineage II.1 are colored in red. Metadata is visualized 969 
on the concentric rings in compliance to the legend, from the inside to outside; 970 
1. Country of origin, 2. Year of isolation, 3. Presence of IncHI2 replicon, 4-8. 971 
Presence of multidrug resistance markers (MDR; bla, cat, sul, dfrA), mphA, 972 
blaSHV-2A, qnrS and gyrA antimicrobial resistance markers (AMR). 973 
Reference strains A130 (lineage I), D23580 (lineage II) and 10433_3 974 
(sublineage II.1) are indicated in blue, as well as strain 5390_4. Branch 975 
lengths represent the number of SNPs as indicated in the scale bar. The tree is 976 
publicly available on microreact (https://microreact.org/project/ZfwCFTj2-977 
/d9f0ce6f; Supplemental Fig. 2). 978 
b. Maximum likelihood phylogenetic tree of all S. Typhimurium ST313 lineage 979 
II strains included in this study, based on mapping against sublineage II.1 980 
reference strain 10433_3 (this study). The tree is based on 1207 chromosomal 981 
SNPs. A collapsed branch is annotated with a grey triangle. The tree is rooted 982 
with S. Typhimurium strain DT2B, a European ST313 strain. Branches of S. 983 
Typhimurium ST313 sublineage II.1 are colored in red. Metadata is visualized 984 
lanes in compliance to the legend, from left to right; 1. Country of origin, 2. 985 
  36 
Year of isolation, 3. Presence of IncHI2 replicon, 4-8. Presence of multidrug 986 
resistance markers (MDR; bla, cat, sul, dfrA), mphA, blaSHV-2A, qnrS and 987 
gyrA AMR markers. 9. Location in the Democratic Republic of the Congo. 988 
Reference strain 10433_3 (sublineage II.1) is indicated in blue. Branch lengths 989 
are indicated and represent the number of SNPs. 990 
 991 
Figure 3: Bayesian time-tree of African S. Typhimurium ST313 lineage II 992 
Bayesian maximum clade credibility phylogeny of African S. Typhimurium ST313 993 
lineage II and sublineage II.1 isolates. The time-tree is based on 1187 SNP differences 994 
detected across the whole core genome of the 175 lineage II and II.1 sequenced 995 
isolates. The tree was visualized and colored in Figtree v1.4.2. A divergence date 996 
(median estimate and its respective 95% HPD) is indicated for the ST313 II.1 997 
sublineage. Tree tips are color coded according to their country of origin (colored by 998 
legend at top). 999 
 1000 
Figure 4: IncHI2 resistance plasmid pCST313 from S. Typhimurium ST313 1001 
sublineage II.1 1002 
The genetic makeup of the pCST313 resistance plasmid from isolate 10433_3 is 1003 
given. pCST313 is 274,695 nucleotides long, and has 290 annotated genes. 1004 
Annotations are shown on the outer circle and coloured by gene function: resistance 1005 
genes (red), plasmid functions (blue), transposon related genes (green), metabolism 1006 
functions (white) and hypothetical genes (grey). The inner five circles show pairwise 1007 
similarity regions of 100 % with previously reported IncHI2 plasmids in S. 1008 
Typhimurium ST313 (pKST313 from Kenya (LN794248) and pSTm-A54650 from 1009 
Malawi (LK056646)), a draft assembly from the IncHI2 plasmid of strain 5390_4 1010 
  37 
from Kisangani (this study) and R478 IncHI2 from Serratia marescens isolated in the 1011 
USA (BX664015). 1012 
 1013 
Figure 5: Genomic changes in S. Typhimurium ST313 sublineage II.1 versus 1014 
ST313 lineage II 1015 
An schematic overview of the genomic differences between S. Typhimurium ST313 1016 
sublineage II.1 versus ST313 lineage II are schematically shown. The genetic changes 1017 
in S. Typhimurium sublineage II.1 include the acquisition of a new resistance 1018 
plasmid, pCST313, the loss of the flagellin fljB gene and the acquisition of 38 single 1019 
nucleotide polymorphisms (SNPs) in the chromosome sequence. 1020 
 1021 
Figure 6: Increased host adaptation of sublineage II.1 1022 
a. Invasiveness index values for all S. Typhimurium sequences included in this 1023 
study, grouped into lineage, as calculated by the method of Wheeler et al. 1024 
(2018). Summary of statistics on different clades: Non-ST313: median = 1025 
0.184, SD = 0.093; Lineage I: median = 0.185, SD = 0.003; Lineage II: 1026 
median = 0.205, SD = 0.005; Lineage II.1: median = 0.222, SD = 0.004. The 1027 
groups were compared using a Mann Whitney U test. Boxplot center lines 1028 
represent median values, box limits present upper and lower quartiles; 1029 
whiskers the 1.5 interquartile range and points the outliers. 1030 
b. Red, dry and rough (RDAR) morphotype 80 of S. Typhimurium ST313 lineage 1031 
II strain D23580 
12
, S. Typhimurium ST313 lineage II.1 strain 10433_3 (this 1032 
study) and a S. Typhimurium ST313 lineage II D23580 asmA knock-out strain 1033 
(this study). 1034 
 1035 
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